High-throughput screening for small-molecule activators of neutrophils: Identification of novel N-formyl peptide receptor agonists

Igor A. Schepetkin, Liliya N. Kirpotina, Andrey Ivanovich Khlebnikov, Mark T. Quinn

Результат исследований: Материалы для журналаСтатья

49 Цитирования (Scopus)

Выдержка

We screened a chemolibrary of drug-like molecules for their ability to activate reactive oxygen species (ROS) production in murine phagocytes, and we identified 26 novel compounds with potent neutrophil activating properties. We used substructure screening, fragment-focusing, and structure-activity relationship analyses to further probe the parent library and defined at least two groups of activators of ROS production in murine neutrophils: t-butyl benzene and thiophene-2-amide-3-carboxylic ester derivatives. Further studies of the active compounds revealed 11 compounds that activated ROS production in human neutrophils, and six of these compounds also activated intercellular Ca2+ mobilization and chemotaxis in human neutrophils. Of the latter compounds, compound 14 (1,3-benzodioxolane-5-carboxylic acid 4′-benzyloxy-3′-methoxybenzylidene-hydrazide) activated neutrophils at nanomolar concentrations, and Ca2+ mobilization was inhibited by pertussis toxin and N-t-butoxycarbonyl-Phe-Leu-Phe-Leu-Phe (Boc-2), an antagonist of formyl peptide receptors (FPR/FPRL1). Likewise, activation by compound 14 was desensitized after N-formyl-Met-Leu-Phe pretreatment. Similar biological activities were found for compound 104 (1,3-benzodioxolane-5- carboxylic acid 3′-bromo-5′-ethoxy-4′- hydroxybenzylidenehydrazide), an analog of compound 14. Furthermore, conformational analysis of the activators of chemotaxis and Ca2+ mobilization showed a high degree of similarity in distances between pharmacophore points of compounds 14 and 104 with a model of FPR published by Edwards et al. (Mol Pharmacol 68:1301-1310, 2005), indicating that conformational features of the agonists identified here are structurally compatible with steric constraints of the ligand-binding pocket of the receptor. Based on these results, we conclude that compounds 14 and 104 represent novel small-molecule agonists of FPR. These studies enhance our understanding of FPR ligand/receptor interactions and structure/activity relationships of phagocyte agonists.

Язык оригиналаАнглийский
Страницы (с-по)1061-1074
Число страниц14
ЖурналMolecular Pharmacology
Том71
Номер выпуска4
DOI
СостояниеОпубликовано - апр 2007
Опубликовано для внешнего пользованияДа

Отпечаток

Formyl Peptide Receptor
Neutrophils
Reactive Oxygen Species
Chemotaxis
Structure-Activity Relationship
Phagocytes
Carboxylic Acids
Ligands
Thiophenes
Aptitude
Pertussis Toxin
Benzene
Amides
Libraries
Esters
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology

Цитировать

High-throughput screening for small-molecule activators of neutrophils : Identification of novel N-formyl peptide receptor agonists. / Schepetkin, Igor A.; Kirpotina, Liliya N.; Khlebnikov, Andrey Ivanovich; Quinn, Mark T.

В: Molecular Pharmacology, Том 71, № 4, 04.2007, стр. 1061-1074.

Результат исследований: Материалы для журналаСтатья

@article{3be5e9483fcf4c89975bb62cb55dc381,
title = "High-throughput screening for small-molecule activators of neutrophils: Identification of novel N-formyl peptide receptor agonists",
abstract = "We screened a chemolibrary of drug-like molecules for their ability to activate reactive oxygen species (ROS) production in murine phagocytes, and we identified 26 novel compounds with potent neutrophil activating properties. We used substructure screening, fragment-focusing, and structure-activity relationship analyses to further probe the parent library and defined at least two groups of activators of ROS production in murine neutrophils: t-butyl benzene and thiophene-2-amide-3-carboxylic ester derivatives. Further studies of the active compounds revealed 11 compounds that activated ROS production in human neutrophils, and six of these compounds also activated intercellular Ca2+ mobilization and chemotaxis in human neutrophils. Of the latter compounds, compound 14 (1,3-benzodioxolane-5-carboxylic acid 4′-benzyloxy-3′-methoxybenzylidene-hydrazide) activated neutrophils at nanomolar concentrations, and Ca2+ mobilization was inhibited by pertussis toxin and N-t-butoxycarbonyl-Phe-Leu-Phe-Leu-Phe (Boc-2), an antagonist of formyl peptide receptors (FPR/FPRL1). Likewise, activation by compound 14 was desensitized after N-formyl-Met-Leu-Phe pretreatment. Similar biological activities were found for compound 104 (1,3-benzodioxolane-5- carboxylic acid 3′-bromo-5′-ethoxy-4′- hydroxybenzylidenehydrazide), an analog of compound 14. Furthermore, conformational analysis of the activators of chemotaxis and Ca2+ mobilization showed a high degree of similarity in distances between pharmacophore points of compounds 14 and 104 with a model of FPR published by Edwards et al. (Mol Pharmacol 68:1301-1310, 2005), indicating that conformational features of the agonists identified here are structurally compatible with steric constraints of the ligand-binding pocket of the receptor. Based on these results, we conclude that compounds 14 and 104 represent novel small-molecule agonists of FPR. These studies enhance our understanding of FPR ligand/receptor interactions and structure/activity relationships of phagocyte agonists.",
author = "Schepetkin, {Igor A.} and Kirpotina, {Liliya N.} and Khlebnikov, {Andrey Ivanovich} and Quinn, {Mark T.}",
year = "2007",
month = "4",
doi = "10.1124/mol.106.033100",
language = "English",
volume = "71",
pages = "1061--1074",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "4",

}

TY - JOUR

T1 - High-throughput screening for small-molecule activators of neutrophils

T2 - Identification of novel N-formyl peptide receptor agonists

AU - Schepetkin, Igor A.

AU - Kirpotina, Liliya N.

AU - Khlebnikov, Andrey Ivanovich

AU - Quinn, Mark T.

PY - 2007/4

Y1 - 2007/4

N2 - We screened a chemolibrary of drug-like molecules for their ability to activate reactive oxygen species (ROS) production in murine phagocytes, and we identified 26 novel compounds with potent neutrophil activating properties. We used substructure screening, fragment-focusing, and structure-activity relationship analyses to further probe the parent library and defined at least two groups of activators of ROS production in murine neutrophils: t-butyl benzene and thiophene-2-amide-3-carboxylic ester derivatives. Further studies of the active compounds revealed 11 compounds that activated ROS production in human neutrophils, and six of these compounds also activated intercellular Ca2+ mobilization and chemotaxis in human neutrophils. Of the latter compounds, compound 14 (1,3-benzodioxolane-5-carboxylic acid 4′-benzyloxy-3′-methoxybenzylidene-hydrazide) activated neutrophils at nanomolar concentrations, and Ca2+ mobilization was inhibited by pertussis toxin and N-t-butoxycarbonyl-Phe-Leu-Phe-Leu-Phe (Boc-2), an antagonist of formyl peptide receptors (FPR/FPRL1). Likewise, activation by compound 14 was desensitized after N-formyl-Met-Leu-Phe pretreatment. Similar biological activities were found for compound 104 (1,3-benzodioxolane-5- carboxylic acid 3′-bromo-5′-ethoxy-4′- hydroxybenzylidenehydrazide), an analog of compound 14. Furthermore, conformational analysis of the activators of chemotaxis and Ca2+ mobilization showed a high degree of similarity in distances between pharmacophore points of compounds 14 and 104 with a model of FPR published by Edwards et al. (Mol Pharmacol 68:1301-1310, 2005), indicating that conformational features of the agonists identified here are structurally compatible with steric constraints of the ligand-binding pocket of the receptor. Based on these results, we conclude that compounds 14 and 104 represent novel small-molecule agonists of FPR. These studies enhance our understanding of FPR ligand/receptor interactions and structure/activity relationships of phagocyte agonists.

AB - We screened a chemolibrary of drug-like molecules for their ability to activate reactive oxygen species (ROS) production in murine phagocytes, and we identified 26 novel compounds with potent neutrophil activating properties. We used substructure screening, fragment-focusing, and structure-activity relationship analyses to further probe the parent library and defined at least two groups of activators of ROS production in murine neutrophils: t-butyl benzene and thiophene-2-amide-3-carboxylic ester derivatives. Further studies of the active compounds revealed 11 compounds that activated ROS production in human neutrophils, and six of these compounds also activated intercellular Ca2+ mobilization and chemotaxis in human neutrophils. Of the latter compounds, compound 14 (1,3-benzodioxolane-5-carboxylic acid 4′-benzyloxy-3′-methoxybenzylidene-hydrazide) activated neutrophils at nanomolar concentrations, and Ca2+ mobilization was inhibited by pertussis toxin and N-t-butoxycarbonyl-Phe-Leu-Phe-Leu-Phe (Boc-2), an antagonist of formyl peptide receptors (FPR/FPRL1). Likewise, activation by compound 14 was desensitized after N-formyl-Met-Leu-Phe pretreatment. Similar biological activities were found for compound 104 (1,3-benzodioxolane-5- carboxylic acid 3′-bromo-5′-ethoxy-4′- hydroxybenzylidenehydrazide), an analog of compound 14. Furthermore, conformational analysis of the activators of chemotaxis and Ca2+ mobilization showed a high degree of similarity in distances between pharmacophore points of compounds 14 and 104 with a model of FPR published by Edwards et al. (Mol Pharmacol 68:1301-1310, 2005), indicating that conformational features of the agonists identified here are structurally compatible with steric constraints of the ligand-binding pocket of the receptor. Based on these results, we conclude that compounds 14 and 104 represent novel small-molecule agonists of FPR. These studies enhance our understanding of FPR ligand/receptor interactions and structure/activity relationships of phagocyte agonists.

UR - http://www.scopus.com/inward/record.url?scp=33947423228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947423228&partnerID=8YFLogxK

U2 - 10.1124/mol.106.033100

DO - 10.1124/mol.106.033100

M3 - Article

C2 - 17229869

AN - SCOPUS:33947423228

VL - 71

SP - 1061

EP - 1074

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 4

ER -